In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...

In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement ...

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Fintel reports that on August 4, 2025, Wolfe Research upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Key Points GAAP revenue surpassed expectations, reaching $12.5 million in Q2 2025, Revenue reached $12.5 million, up approximately 45.3% from the prior year period. Net loss (GAAP) widened to $112.0 ...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company ...

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...